Investigational Drug Information for Miravirsen
✉ Email this page to a colleague
What is the drug development status for Miravirsen?
Miravirsen is an investigational drug.
There have been 5 clinical trials for Miravirsen.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2010.
The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis A. The leading clinical trial sponsors are Santaris Pharma A/S and [disabled in preview].
Summary for Miravirsen
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 47 |
| Japanese Patent Applications | 28 |
| Clinical Trial Progress | Phase 2 (2010-09-01) |
| Vendors | 8 |
Recent Clinical Trials for Miravirsen
| Title | Sponsor | Phase |
|---|---|---|
| Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C | Santaris Pharma A/S | Phase 2 |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection | Santaris Pharma A/S | Phase 2 |
| Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C | Santaris Pharma A/S | Phase 2 |
Clinical Trial Summary for Miravirsen
Top disease conditions for Miravirsen
Top clinical trial sponsors for Miravirsen
US Patents for Miravirsen
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
